# Jan Rekowski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4888690/publications.pdf

Version: 2024-02-01

| 27 | 845 | 623734 14 | 610901 24 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 28 | 28 | 28 | 1244 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial. Nephrology Dialysis Transplantation, 2023, 38, 982-991. | 0.7 | 3 |
| 2 | Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine, 2022, 75, 293-302. | 2.3 | 8 |
| 3 | Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2611-2621. | 2.5 | 2 |
| 4 | Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the Î”SUV<sub>max</sub> Method. Journal of Nuclear Medicine, 2021, 62, 37-42. | 5.0 | 29 |
| 5 | Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. European Urology, 2021, 79, 200-211. | 1.9 | 76 |
| 6 | Characterizing CDK12-Mutated Prostate Cancers. Clinical Cancer Research, 2021, 27, 566-574. | 7.0 | 50 |
| 7 | Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discovery, 2021, 11, 1118-1137. | 9.4 | 124 |
| 8 | Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery, 2021, 11, 2812-2827. | 9.4 | 78 |
| 9 | HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research, 2021, 81, 6207-6218. | 0.9 | 25 |
| 10 | CSF and blood Kallikrein-8: a promising early biomarker for Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 40-48. | 1.9 | 16 |
| 11 | Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determination. Data in Brief, 2020, 28, 104976. | 1.0 | 1 |
| 12 | Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. European Journal of Cancer, 2020, 124, 25-36. | 2.8 | 67 |
| 13 | Impact of complete surgical resection on outcome in aggressive nonâ€Hodgkin lymphoma treated with immunochemotherapy. Cancer Medicine, 2020, 9, 8386-8396. | 2.8 | 5 |
| 14 | Score performance of SAPS 2 and SAPS 3 in combination with biomarkers IL-6, PCT or CRP. PLoS ONE, 2020, 15, e0238587. | 2.5 | 2 |
| 15 | Metabolic tumor volume, cancer cell fraction, and prognosis â€“ the case of T-cell/histiocyte-rich large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 1372-1379. | 1.3 | 3 |
| 16 | Baseline and interim PETâ€based outcome prediction in peripheral Tâ€cell lymphoma: A subgroup analysis of the PETAL trial. Hematological Oncology, 2020, 38, 244-256. | 1.7 | 18 |
| 17 | Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome. Blood Cancer Journal, 2019, 9, 67. | 6.2 | 5 |
| 18 | The predictive performance of SAPS 2 and SAPS 3 in an intermediate care unit for internal medicine at a German university transplant center; A retrospective analysis. PLoS ONE, 2019, 14, e0222164. | 2.5 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the â€œPositron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomasâ€•(PETAL) trial. Annals of Hematology, 2019, 98, 897-907. | 1.8 | 24 |
| 20 | Positron Emission Tomographyâ€“Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2018, 36, 2024-2034. | 1.6 | 176 |
| 21 | Interim PET-Based Outcome Prediction in Diffuse Large B-Cell Lymphoma Patients Participating in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) Trial: Comparison of the Delta SUV Max Method and the Deauville 5-Point Scale. Blood, 2018, 132, 1696-1696. | 1.4 | 0 |
| 22 | Phase II doseâ€“response trials: A simulation study to compare analysis method performance under design considerations. Journal of Biopharmaceutical Statistics, 2017, 27, 885-901. | 0.8 | 0 |
| 23 | Hepatic artery and biliary complications in liver transplant recipients with radioembolization bridging treatment for hepatocellular carcinoma. Clinical Transplantation, 2017, 31, e13096. | 1.6 | 7 |
| 24 | Arthroscopic three-dimensional autologous chondrocyte transplantation using spheroids for the treatment of full-thickness cartilage defects of the hip joint. Knee Surgery, Sports Traumatology, Arthroscopy, 2016, 24, 2032-2037. | 4.2 | 52 |
| 25 | Is early treatment of cam-type femoroacetabular impingement the key to avoiding associated full thickness isolated chondral defects?. Knee Surgery, Sports Traumatology, Arthroscopy, 2016, 24, 2332-2337. | 4.2 | 32 |
| 26 | Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive Lymphomas. Blood, 2015, 126, 3880-3880. | 1.4 | 0 |
| 27 | Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas â€“ a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL) Tj ETQq1 1 0.784314 rgBT /Overloc | 1.4 | 0 |